Comment on “Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?”

American Heart Journal Plus: Cardiology Research and Practice · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles